Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03974386
Other study ID # 201808098DIPC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2019
Est. completion date August 20, 2020

Study information

Verified date March 2021
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In recent years, many studies have pointed out that bacterial toxin and cytokine storm are the main causes of shock and multiple organ failure in patients with sepsis. Endotoxin is the main vehicle for systemic inflammatory reaction caused by gram-negative bacteria which induce sepsis. Endotoxin binds to Toll- Like receptor 4 (TLR4) trigger a cytokine storm. The amount of endotoxin is associated with shock, insufficient intestinal perfusion, and poor prognosis. Therefore, clinicians try to use various methods to antagonize the action of endotoxin, which can reduce the cytokine storm and inflammatory response to improve the prognosis of sepsis. Continuous venous venous hemofiltration plays a role in blood purification in septic shock. With different hemofiltration filters, it has different effects. By removing the inflammatory mediators caused by bacterial toxins and cytokines, shock can be improved. The study plans to receive patients with septic shock and use a hemofiltration filter that adsorbs endotoxin and removes cytokines (oXiris, Baxter Healthcare) to perform continuous venous venous hemofiltration in addition to basic septic shock resuscitation. The effect on the concentration of cytokines in the blood, the infusion dose of inotropics, the fluid balances, and the degree of organ damage was evaluated. It is hoped that the results of this pilot study can lead us to subsequent randomized clinical trials to explore whether this filter can improve the prognosis of septic shock patients.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date August 20, 2020
Est. primary completion date July 17, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Patients who meet all criteria (A+B+C): - A) Identified infection source under adequate treatment - B) Sepsis (the sequential organ failure assessment score rise 2 points or more) - C) Severe septic shock (serum lactate > 2 mmol/L; need continuous norepinephrine infusion to maintain adequate blood pressure, of which dosage is > 0.2 mcg/kg/min for more than 1 hour or >0.1 mcg/kg/min for more than 3 hours ) Exclusion Criteria: - Onset of severe septic shock more than 24 hours - Received continuous renal replacement therapy within 24 hours before enrollment - Serum white blood cell count count < 1000 cells/µL or Platelet count < 50000 cells/µL - History of allergy to heparin - Received cardiopulmonary resuscitation within 4 weeks before enrollment - ICU admission due to severe septic shock within 2 months - Patients or Family had chosen palliative care and signed an agreement to deny aggressive treatment - Pregnancy - APACHE II Score > 30 at enrollment - Non-native speakers

Study Design


Related Conditions & MeSH terms


Intervention

Device:
oXiris blood purification set
Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference of serum interleukin-6 level Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of serum interleukin-6 level Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of serum interleukin-6 level Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of serum interleukin-1ß level Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of serum interleukin-1ß level Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of serum interleukin-1ß level Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of serum interleukin-10 level Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of serum interleukin-10 level Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of serum interleukin-10 level Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of serum procalcitonin level Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of serum procalcitonin level Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of serum procalcitonin level Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of mean arterial pressure Comparison to enrollment 24 hours
Secondary Difference of mean arterial pressure Comparison to enrollment 48 hours
Secondary Difference of mean arterial pressure Comparison to enrollment 72 hours
Secondary Difference of cardiac output Comparison to enrollment 24 hours
Secondary Difference of cardiac output Comparison to enrollment 48 hours
Secondary Difference of cardiac output Comparison to enrollment 72 hours
Secondary Difference of norepinephrine infusion rate Comparison to enrollment 24 hours
Secondary Difference of norepinephrine infusion rate Comparison to enrollment 48 hours
Secondary Difference of norepinephrine infusion rate Comparison to enrollment 72 hours
Secondary Difference of the sequential organ failure assessment score Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of the sequential organ failure assessment score Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of the sequential organ failure assessment score Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of serum endocan level Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of serum endocan level Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of serum endocan level Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of serum diamine oxidase level Comparison to enrollment or between 2 groups 24 hours
Secondary Difference of serum diamine oxidase level Comparison to enrollment or between 2 groups 48 hours
Secondary Difference of serum diamine oxidase level Comparison to enrollment or between 2 groups 72 hours
Secondary Difference of daily IV fluids Comparison between 2 groups 24 hours
Secondary Difference of daily IV fluids Comparison between 2 groups 48 hours
Secondary Difference of daily IV fluids Comparison between 2 groups 72 hours
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Completed NCT02306928 - PK Analysis of Piperacillin in Septic Shock Patients N/A
Completed NCT02204852 - Co-administration of Iloprost and Eptifibatide in Septic Shock Patients Phase 2